ll37
Peptideexperimental
Cathelicidin antimicrobial peptide (CAMP) is an antimicrobial peptide encoded in the human by the CAMP gene. The active form is LL-37. In humans, CAMP encodes the peptide precursor CAP-18, which is processed by proteinase 3-mediated extracellular cleavage into the active form LL-37. — Wikipedia
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 8, 2015 (NCT02225366)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCathelicidin antimicrobial peptide ↗
- WikipediaCathelicidin ↗
Also known as
- ll37
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04098562 | Phase 2 | Oct 31, 2019 | University of Indonesia |
| NCT02225366 | Phase 1/Phase 2 (Phase 2) | Jul 8, 2015 | National Cancer Institute (NCI), University of Texas at Houston |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2015 |
| University of Indonesia | Academic/Hospital | 1 | 1 | 1 | 2019 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2015 |
3 organizations
Page 1 / 1